89bio Inc Cash Flow Conversion Efficiency
89bio Inc cash flow conversion efficiency. Based on the latest financial reports, 89bio Inc (ETNB) has a cash flow conversion efficiency ratio of -0.192x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-100.42 Million) by net assets ($521.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of 89bio Inc (2018–2024)
Cash flow conversion efficiency of 89bio Inc from 2018 to 2024. This chart illustrates how 89bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View 89bio Inc share price for real-time trading data and today's change.
89bio Inc Cash Flow Conversion Ratio Explained
89bio Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
89bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 89bio Inc ranked by their cash flow conversion efficiency. Also see ETNB market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chongqing Rural Commercial Bank Co. Ltd
F:C3B
|
-0.072x |
|
GavYam Lands Corp Ltd
TA:GVYM
|
0.019x |
|
Schiehallion Fund Ltd
LSE:MNTN
|
-0.005x |
|
Bank of N.T. Butterfield & Son Ltd
NYSE:NTB
|
0.052x |
|
Hangzhou Robam Appliances Co Ltd
SHE:002508
|
0.022x |
|
Sime Darby Property Bhd
KLSE:5288
|
0.033x |
|
Yangtze Optical Electronic Co. Ltd. A
SHG:688143
|
N/A |
|
Hilltop Holdings Inc
NYSE:HTH
|
0.123x |
Annual Cash Flow Conversion Efficiency for 89bio Inc (2018–2024)
The table below shows the annual cash flow conversion efficiency of 89bio Inc from 2018 to 2024. Review how financially flexible is 89bio Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $400.79 Million | $-367.82 Million | -0.918x | -281.00% |
| 2023-12-31 | $536.31 Million | $-129.19 Million | -0.241x | +54.90% |
| 2022-12-31 | $151.83 Million | $-81.09 Million | -0.534x | +12.39% |
| 2021-12-31 | $125.96 Million | $-76.78 Million | -0.610x | -167.54% |
| 2020-12-31 | $202.96 Million | $-46.24 Million | -0.228x | +19.51% |
| 2019-12-31 | $89.94 Million | $-25.46 Million | -0.283x | -136.45% |
| 2018-12-31 | $-16.06 Million | $-12.47 Million | 0.777x | -- |
About 89bio Inc
89bio, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of metabolic dysfunction-associated steatohepatitis and hypertriglyceridemia. 89bio, Inc. was formerly kn… Read more